ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

ImmunityBio, Inc.NASDAQ: IBRX

Accumulated OCI · Q3 FY2026 · quarter ended Sep 2026

Accumulated OCI rises 437.9% from a year ago

Accumulated OCI stood at $26.88M at the end of Q3 FY2026, up 437.9% from a year earlier and down 1.5% from the prior quarter. Over 3 fiscal years it compounded at +440.9% a year.

Context

  • Accumulated OCI amounted to 4.4% of total assets at the end of Q3 FY2026, up 3.4 pp from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +437.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$26.88M-1.5% QoQ
Last fiscal yearDec 2025
$28.96M+2317.0% YoY
Year agoSep 2025
$5M+437.9% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+437.9%——
1 year+2317.0%——
3-year CAGR+440.9%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
28.96M USD
Year-over-year change
+2317.0%
4-year CAGR
+822.4%

Accumulated OCI vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +437.9% is the highest of 11, against a peer median of -42.2%.
  • Accumulated OCI amounts to 4.4% of total assets for IBRX, versus a peer median of 0.2%.
IBRX Competitors
Accumulated OCI for IBRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LEGNLegend Biotech CorporationSep 2026$122.6M USD+5.8%+102.7%7.3%
IBRXImmunityBio, Inc.Sep 2026$26.88M USD+437.9%+440.9%4.4%
IOVAIovance Biotherapeutics, Inc.Sep 2026$13.85M USD-14.0%—1.4%
MRNAModerna, Inc.Sep 2026$8M USD-70.4%—0.1%
BNTXBioNTech SEJun 2026€0 EUR+100.0%—0.0%
ATRAAtara Biotherapeutics, Inc.Mar 2026$0 USD+100.0%—0.0%
NKTXNkarta, Inc.Mar 2026-$130K USD-119.9%—0.0%
ALLOAllogene Therapeutics, Inc.Mar 2026-$183K USD-525.6%—0.0%
VIRVir Biotechnology, Inc.Mar 2026-$3.48M USD-76.4%—0.3%
IMTXImmatics N.V.Mar 2026-€6.72M EUR-300.2%—1.2%
IMCRImmunocore Holdings plcMar 2026-$35.37M USD-6.9%—3.3%
Peer median (excluding IBRX) —-42.2%+102.7%0.2%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents181.1M104.64M265.45M143.43M88.33M
Short-term Investments136.02M2.54M1.01M6.38M154.48M
Net Receivables1.33M1.89M3.17M2.65M42.62M
Inventory0008.27M910K
Other Current Assets2.96M2.9M5.21M1.3M3.89M
Total Current Assets334.35M140.58M294.08M184.59M314.88M
Property, Plant & Equipment (Net)119.17M189.45M182.68M170.46M147.55M
Goodwill000910K910K
Intangible Assets1.42M20M17.09M15.02M13.04M
Long-term Investments7.6M840K891K700K10.48M
Tax Assets00000
Other Non-current Assets6.38M11.49M9.7M11.26M15.05M
Total Non-current Assets134.56M221.78M210.37M198.35M187.02M
Total Assets468.91M362.36M504.45M382.93M501.9M
Account Payables11.42M21.02M9.2M6.73M6.98M
Short-term Debt299.24M431.9M009.29M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities16.52M19.74M18.31M15.98M25.42M
Total Current Liabilities369M500.86M58.28M54.94M61.75M
Long-term Debt306.35M241.27M681.54M461.88M835.16M
Deferred Tax Liabilities162K0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities249K22.09M310.63M319.42M70.89M
Total Non-current Liabilities343.83M311.32M1.03B816.12M939.72M
Total Liabilities712.82M812.18M1.09B871.06M1B
Common Stock40K42K67K85K101K
Retained Earnings(1.96B)(2.38B)(2.96B)(3.38B)(3.73B)
Accumulated OCI4K183K10K1.2M28.96M
Other Stockholders Equity0000909K
Minority Interest(1.74M)(2.49M)1.05M969K895K
Total Equity(243.91M)(449.82M)(585.94M)(488.13M)(499.57M)
Total Debt645.66M723.77M726.72M504.17M878.12M
Net Debt464.56M619.13M461.27M360.74M789.78M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.